We would continue to expect the sorting process to favor Aphria Inc (OTCMKTS:APHQF). The stock has clear future catalysts lined up and was not carried higher into the Canadian Adult-Use announcement last week on an air pocket or on a raft of hype and hyperbole as so many other companies were. Shares of APHQF also just triggered key technical support and successfully held the 200-day MA. In addition, the company has manned a first-class team from top to bottom and keeps adding new talent.
As a case in point, the company just announced Dr. Jonathan Simone, Ph.D. as the Company’s Director of Research and Clinical Studies. According to the release, “Dr. Simone joined Aphria in July 2018 and serves as the primary liaison between the Company’s science, technical and medical division teams and outside medical, academic and clinical centers. He is also spearheading Aphria’s participation in various clinical studies.”
Aphria Inc (OTCMKTS:APHQF) bills itself as a company that produces, supplies, and sells medical cannabis in Canada. Its cannabis products include dried flowers and cannabis oils. APHQF sells its products through its online store and telephone orders, as well as MMPR licensed producers.
The company offers sativa, indica, and hybrid medical marijuana products, as well as cannabis oils. It also provides support services in the form of medical consultations, group therapies, and rehabilitation to veteran and first responders.
The company sells its products through its online store or phones, as well as engages in the wholesale shipping of medical marijuana plant cuttings and dried buds to other licensed producers. Aphria Inc. is headquartered in Leamington, Canada.
According to press materials, “Aphria is a leading global cannabis company driven by an unrelenting commitment to our people, product quality and innovation. Headquartered in Leamington, Ontario – the greenhouse capital of Canada – Aphria has been setting the standard for the low-cost production of safe, clean and pure pharmaceutical-grade cannabis at scale, grown in the most natural conditions possible. Focusing on untapped opportunities and backed by the latest technologies, Aphria is committed to bringing breakthrough innovation to the global cannabis market. The Company’s portfolio of brands is grounded in expertly-researched consumer insights designed to meet the needs of every consumer segment. Rooted in our founders’ multi-generational expertise in commercial agriculture, Aphria drives sustainable long-term shareholder value through a diversified approach to innovation, strategic partnerships and global expansion, with a presence in more than 10 countries across 5 continents.”
Find out when $APHQF reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
As noted above, APHQF just announced Dr. Jonathan Simone, PhD as the Company’s Director of Research and Clinical Studies. In all, we’ve seen recent action on the downside as the cannabis space pulls back in the wake of the Canadian legalization announcement last week. The stock is down about -10% over the past week. However, we are now coming off a perfect and bullish test and hold of the 200-day simple moving average.
“As the post-legalization era unfolds, Aphria remains committed to supporting our patients and the advancement of medical cannabis around the world through much-needed clinical research studies,” said Vic Neufeld, Chief Executive Officer of Aphria. “Jonathan is a rising star in the medical cannabis research community and we are pleased to welcome him to the Aphria family. He is uniquely qualified to accelerate Aphria’s support for and participation in medical cannabis clinical research to further the Company’s continued global leadership in medical cannabis.”
In addition, the name has registered increased average transaction volume recently, with the past month seeing 91% over the long run average.
Now commanding a market cap of $3.11B, APHQF has a significant war chest ($314M) of cash on the books, which is balanced by virtually no total current liabilities. APHQF is pulling in trailing 12-month revenues of $44.1M. In addition, the company is seeing major top-line growth, with y/y quarterly revenues growing at 117.2%. This is an exciting story, and we look forward to a follow-up chapter as events transpire. Sign-up for continuing coverage on shares of $APHQF stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!
Disclosure: we hold no position in $APHQF, either long or short, and we have not been compensated for this article.